HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study
Posted: Jul 13, 2018
CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study image

Celgene has amended the protocol of the Phase II KarMMa study to increase the dose and number of patients to be enrolled for the CAR T bb2121 treatment. The study is currently open for relapsed/refractory multiple myeloma. 

Based on prior data, the dose in the Phase II study has been increased to 15 - 45 x 10CAR T-cells from 15 - 30 x 10cells. The study will enroll up to 140 patients.  

The Phase I study (called CRB-401) will also increase enrollment to an additional 20 patients and the dose range will be the same as the KarMMa study. 

Celgene and bluebird bio anticipate regulatory approval for bb2121 for multiple myeloma in 2020. 


The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube